Table 33Adverse events: Glatiramer acetate compared with interferons in relapsing-remitting multiple sclerosis

Adverse eventInterferon beta-1b SC (Betaseron®) 250μg or 500μg59Interferon beta-1a SC (Rebif®) 44 μg58Glatiramer acetate (Copaxone®)58, 59
Flu-like syndrome40%–45%31%6% (BEYOND), P<0.0001
1% (REGARD), P<0.0001
Any injection site reaction48%–55%58% (BEYOND), P=0.0005
Injection site pruritus1%–2%2%8% (BEYOND), P<0.0001
20%, (REGARD), P<0.0001
Injection site swelling1%1%4%, BEYOND), P=0.005
11%, (REGARD), P<0.0001
Injection site induration1%–2%2%5% (BEYOND), P<0.0001
7%, (REGARD), P=0.005
Fever9%–13%6%5% (BEYOND), P=0.003
4% (REGARD), P=0.18
Myalgias6%2% (REGARD), P=0.01
Fatigue22%–24%NR21% (BEYOND), NS
Headache32%–33%19%27% (BEYOND), NS
9%, P<0.0001
Increased AST9%–13%NR3% (BEYOND), P<0.0001
Increased ALT11%–16%6%4% (BEYOND), P<0.0001

1% (REGARD), P=0.002
Post injection systemic reaction5%–6%0%17% (BEYOND)

5% (REGARD), P<0.0001
Withdrawal due to adverse eventNR6%5% (REGARD), NS

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; NR, not reported; SC, subcutaneous.

From: Results

Cover of Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis
Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].
Smith B, Carson S, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2010 Aug.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.